自第一个EGFR-TKI批准以来20年,gefitinib:洞察力和前性
Satyam Singh1, Sushabhan Sadhukhan2, Avinash Sonawane1
1Department of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Madhya Pradesh 453 552, India.
针对表皮生长因子受体 (EGFR) 对于癌症治疗至关重要. 本综述探讨了克服对EGFR抑制剂的耐药性,并讨论了改善癌症治疗的新疗法策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 皮表皮生长因子受体 (EGFR) 在癌症进展中起着关键作用,包括血管新生,分化和迁移.
- 向EGFR是一种有效的策略,用于治疗非小细胞肺癌 (NSCLC),胰腺癌和质母细胞瘤.
- 第一代,第二代和第三代EGFR氨酸激酶抑制剂 (EGFR-TKI) 已显示出治疗效果.
研究的目的:
- 审查过去20年来EGFR向癌症治疗的突破.
- 讨论克服对EGFR抑制剂的内在和获得性耐药性的策略.
- 突出开发新型EGFR向治疗的新挑战,局限性和未来方向.
主要方法:
- 对EGFR抑制剂和耐药机制的研究进行了全面的文献综述.
- 对克服化疗耐药性的近期进展进行分析.
- 探索超越传统TKI的新兴治疗方式.
主要成果:
- 在了解EGFR突变和抵抗机制方面取得了重大进展.
- 目前正在开发各种策略来规避耐药性,包括新兴抑制剂代和替代治疗方法.
- 像第四代EGFR-TKI,,纳米体和PROTAC等新兴疗法显示出有前途.
结论:
- 尽管取得了进展,但耐药性仍然是EGFR向癌症治疗的主要挑战.
- 对新型抑制剂和组合策略的持续研究至关重要.
- 未来的方向包括开发下一代EGFR抑制剂和探索创新的治疗方式,如PROTACs,以改善患者的治疗结果.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
相关概念视频
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
